Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis A Randomized Clinical Trial

More patients met primary outcome [minimal manifestation status of MG without prednisone at 12 months and without clinical relapse at 15 months] in rapid vs slow-tapering arm (39%] vs 9%). Risk Ratio: 3.61 (95%CI, 1.64-7.97 P<0 .001) after adjusting for centre / thymectomy.

JAMA Neurology